Published in Buzzworthy, 2017
The era of the ‘smart drugs’ has well and truly begun. With the promise of cognitive enhancement, creative expansion, and heightened memory function for users, the potential of these supplements is undeniably riveting, and with growing popularity, they appear set to make profound social and economic impacts in the near future. Otherwise known as Nootropics, the family of ‘smart drugs’ encompasses a broad collection of stimulants that have been adopted to improve cognitive function from those deep-seated in working culture such as caffeine to amphetamine-based pharmaceuticals such as Adderall and dextroamphetamine.
Whilst the greater number of these drugs have well-established cultures and substantial histories of scientific investigation, a small number are little-researched and, with burgeoning global popularity, have become controversial in use for precisely that reason.
In recent years, Modafinil has become one of the most talked-about nootropics, hailed by many as a wonder drug and infiltrating university campuses and the offices of Silicon Valley alike. Modafinil is rapidly being adopted as a driving force in environments where sleep is not a priority and the resources to exceed depend upon superhuman qualities of productivity. It is the drug of choice in a global marketplace dominated by the obsessively competitive. Originally developed as an experimental treatment for narcolepsy in the 1980s, Modafinil belongs to a family of drugs known as Eugeroics, which are designed to promote wakefulness in patients with clinically-defined sleep disorders.